Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80 mg) Orally Administered Once Daily for 35 Days in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. A Double Blind, Parallel Group, Placebo-controlled and Randomized Study.

Next Previous
Trial Profile

A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80 mg) Orally Administered Once Daily for 35 Days in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. A Double Blind, Parallel Group, Placebo-controlled and Randomized Study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elafibranor (Primary)
  • Indications Glucose intolerance; Metabolic syndrome; Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Genfit

Most Recent Events

  • 27 May 2013 A combined analysis of four phase IIa studies was published in Hepatology, according to a GENFIT media release.
  • 04 Aug 2011 Results published in the Diabetes Care.
  • 17 Jan 2011 Actual initiation date (Jun 2009), lead trial investigators (Remy Hanf, Eric Bruckert) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top